Key insights
- Gilead Sciences' executive Mercier sold $422k in stock under a pre-arranged plan. Simultaneously, Gilead is expanding access to its HIV prevention drug and collaborating with Tempus AI to advance its oncology pipeline. Truist Securities raised its price target to $155, maintaining a Buy rating. Overall, the news presents a mixed picture, with positive developments in Gilead's strategic initiatives offset by insider selling, resulting in a slightly positive influence on the US market.
Johanna Mercier, Chief Comm & Corp Aff Officer at Gilead Sciences (NASDAQ:GILD), sold 3,000 shares of common stock on April 15, 2026, at a price of $140.96, for a total value of $422,880.
Following the transaction, Mercier directly owns 128,779 shares of Gilead Sciences. The sale was executed under a Rule 10b5-1 trading plan adopted on February 20, 2025. For deeper insights into Gilead’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities.
In other recent news, Gilead Sciences Inc. has announced a significant expansion in the accessibility of its HIV prevention drug, lenacapavir. The U.S. State Department, PEPFAR, and The Global Fund will invest in expanding access to this twice-yearly injectable medicine, aiming to reach an additional 1 million people, bringing the total to 3 million individuals in high-incidence, resource-limited countries by 2028. Meanwhile, Gilead has also expanded its collaboration with Tempus AI, focusing on advancing its oncology pipeline. This agreement grants Gilead enterprise-wide access to Tempus’ AI-driven Lens platform, which provides extensive datasets and analytical services for oncology research and development.
In terms of analyst activity, Truist Securities has raised its price target for Gilead Sciences to $155 from $152, maintaining a Buy rating. The firm anticipates Gilead’s first quarter of 2026 to align with expectations, with estimated total revenue of $6.94 billion compared to the consensus of $6.91 billion and non-GAAP earnings per share of $1.84 versus the consensus of $1.90. Additionally, RBC Capital reiterated a Sector Perform rating on Gilead, focusing on third-party prescription trends for Yeztugo and assessing its market performance. These developments highlight Gilead’s ongoing strategic initiatives and collaborations in the healthcare sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.